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Prostate cancer is an important health problem. More than 40
000 incident cases of prostate cancer and more than 10 000
prostate cancer related deaths occur each year in the United
Kingdom.1 Prevention, detection, and treatment of localized
prostate cancer remain controversial. Although screening for
prostate cancer with serum prostate specific antigen (PSA)
testing is not approved in the UK, informal screening is common
and has led to a threefold increase in the incidence of prostate
cancer. In the United States, since the introduction of PSA
screening more than 1.3 million men have been diagnosed with
prostate cancer and one million of these have undergone
treatment.2 We update a previous review, highlighting new
findings that deal with clinical questions and future research
needs for the prevention, detection, and treatment of clinically
localized prostate cancer.3
Who is at risk of prostate cancer?
Established risk factors for prostate cancer include increasing
age, black ethnic origin, and a family history of prostate cancer
in a close male relative. The last two factors convey modest risk
compared with age. Prostate cancer is rare before 50 years of
age, and about 80% of cases and 90% of deaths occur in men
over 65.3 Lower urinary tract symptoms (poor flow, urgency,
frequency, hesitancy, nocturia) are common in older men but
not related to prostate cancer development. Testosterone
supplementation for hypogonadism does not clearly increase
prostate cancer development. Although prostate cancer rates
show regional variations and differences between socioeconomic
groups, these are mainly due to differences in rates of PSA
testing.1
The greatest risk factor associated with a prostate cancer
diagnosis is undergoing a PSA blood test.2 3 Using lower
thresholds to indicate abnormality and obtaining larger numbers
of tissue core samples sets off a cascade of events that more
than doubles the incidence of prostate cancer through tumors
that would otherwise never come to clinical attention
(overdiagnosis).
Can prostate cancer be prevented?
Epidemiologic evidence indicates that the most effective way
to reduce prostate cancer incidence is to decrease PSA testing,
raise thresholds used to define an abnormal PSA result (fig 1⇓),4
and lower the number of tissue core samples obtained in men
undergoing a prostate biopsy. In men who receive a PSA test,
use of risk calculators that take other clinical parameters (age,
prostate volume, free to total PSA ratio) into account or a triage
test may help identify men who could avoid a prostate biopsy
and detection of clinically insignificant disease, while still
detecting potentially lethal disease that requires intervention.5 6
The only other strategy shown to reduce prostate cancer
incidence involves 5-α reductase inhibitors (5ARI), which are
approved for treating symptoms of benign prostate enlargement.
Large randomized controlled trials (RCTs) and a systematic
review have shown that 5ARI reduces prostate cancer incidence
but may increase the detection of high risk cancers.7 These drugs
are not approved for prostate cancer prevention. RCTs indicate
that antioxidants, particularly vitamin E and selenium, do not
reduce prostate cancer incidence and should not be used.8Other
widely used options including aspirin, statins, low fat or soy
based diets, and aerobic or weight based exercise are not clearly
effective.
Should men be screened for prostate
cancer with the PSA blood test?
Although such screening is common, the UKNational Screening
Committee and the US Preventive Services Task Force
(USPSTF) recommend against it because the benefit is at best
small (fig 2⇓) and not greater than the harms.9 10 Both groups
recognize that some men will continue to request screening and
some physicians continue to offer it. All major organizations
advise that PSA testing should not be conducted without an
informed discussion of benefits and harms.
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Summary points
Increasing age is the most important risk factor for developing prostate cancer
The most effective way to reduce prostate cancer incidence is to reduce prostate specific antigen (PSA) testing or raise thresholds that
define abnormality
Prostate cancer screening with the PSA blood test results in at most a small reduction in prostate cancer mortality and leads to considerable
diagnostic and treatment related harms
Physicians should recommend against PSA screening for prostate cancer
Most men with prostate cancer detected by PSA testing have tumours that will not cause health problems (overdiagnosed), but almost
all undergo early treatment (overtreated)
The goal of screening programs is to reduce disease specific
and overall morbidity and mortality, not just to detect and treat
more disease. This goal is difficult to achieve because screening
tests are applied to people without symptoms in the hope of
preventing future health problems. Although any potential
benefit occurs in just a few people, all are subjected to the harms
of screening.
The effect of PSA screening on prostate cancer and overall
mortality has been investigated in five large long term
randomized trials.10 11 None has reported a reduction in overall
mortality. Only the European Randomized Study of Screening
for Prostate Cancer (ERSPC), which included results from seven
countries using different screening protocols, identified a
significant reduction in death from prostate cancer. Positive
results mainly came from data from two countries that found
large effects using PSA screening every two to four years.
Although the precise lifetime effect of PSA screening on prostate
cancer mortality remains uncertain, the reduction in prostate
cancer mortality after 10-14 years is 0-1 per 1000men screened,
even for men in the optimal age range of 55-69 years.11
A raised PSA blood test initiates a cascade of diagnostic and
treatment events that have harms and should be considered
before testing (fig 3⇓). Over 10 years, 15-20% of men will have
a PSA test result that triggers a biopsy. About 80% of PSA tests
will be false positive results at widely used cut-off points
(2.5-4.0 ng/mL). Harms and errors related to the diagnostic
transrectal prostate biopsy are common and often serious. The
sampling needles are inserted through the (contaminated)
rectum, with inconsistent use of local anesthetic. The UK
Prostate Testing for Cancer and Treatment (ProtecT) study and
other studies have shown that around a third of men having a
prostate biopsy will have moderate or major bothersome
symptoms, including pain, fever, bleeding, temporary urinary
difficulties, and infection (with sepsis rates of 2-4% from
multiresistant bacteria); 1% will be admitted to hospital and
nearly 0.1% will die.12
Transrectal prostate biopsies are limited by random and
systematic errors. Random errors occur because eight to 12
samples are taken randomly (the location of the cancer is
unknown) and systematic ones occur because certain parts of
the gland are sampled in preference to others. As a result,
indolent disease is detected by chance and clinically important
cancers missed. These errors lead to poor risk attribution; a man
with low risk cancer on transrectal ultrasound guided biopsy
has a one in three chance of harboring higher grade disease,
with the prospect of undertreatment.12 This error in risk
stratification can be used to advise against observation or active
surveillance and recommend surgery or radiotherapy.13
There has been little progress in finding new blood or urinary
biomarkers that could complement or replace PSA because
biomarker development and validation depend on the inaccurate
PSA-transrectal biopsy pathway. Imaging, such as
multi-parametric magnetic resonance imaging (MRI), has shown
promise, especially as it does not detect small low grade
cancers.14 The exact role for MRI is being evaluated in the
PROstate Mr Imaging Study (PROMIS) using a reference
standard biopsy test—template prostate mapping—that
systematically samples the whole prostate.15
The major harms of PSA screening relate to treatment of
detected cancers—about half of those detected would never
cause clinical problems in a man’s lifetime even in the absence
of treatment (overdiagnosis).10 11 Men with such cancers cannot
benefit from detection and treatment and can only be harmed.
Around one in three men over the age of 50 years has prostate
cancer that is unlikely to cause harm during their lifetime; this
greatly exceeds the 3% lifetime risk of dying of prostate cancer
even if left untreated. The use of surgery or radiotherapy to treat
most of these men leads to overtreatment. Treatment related
harms are common and include serious perioperative
complications (rarely death) and long term erectile, urinary, and
bowel dysfunction.
Comparing harms and benefits of any screening test involves
trade-offs that can be difficult to quantify and often involve
differing preferences and values. A recent decision modelling
analysis attempted to derive a common metric to assess the
benefits and harms of screening and subsequent treatment by
assessing quality of life and quality adjusted life years gained
or lost. It used selected findings from the European screening
trial and other published data.16 The analysis found that PSA
screening may reduce or increase quality adjusted survival,
depending on patient values for different health states. The
findings were sensitive to assumptions used. The small reported
gains in quality adjusted survival would probably have
disappeared if mortality andmorbidity results from all screening
and treatment trials had been incorporated.
What treatments should I recommend for
clinically localized prostate cancer?
Treatment options for clinically localized prostate cancer include
watchful waiting or observation, active surveillance, radical
prostatectomy (RP), external beam radiation therapy, interstitial
radiation implants (brachytherapy), cryoablation, androgen
deprivation therapy (ADT), high intensity focused ultrasound,
and focal therapy.3 Treatment recommendations and selection
involve patients’ values and their weighting of the trade-offs in
benefits and harms, as well as physician preferences. A
multidisciplinary approach that includes the patient’s primary
care provider and incorporates the latest findings from
randomized trials or higher quality observational studies can
help a patient make a well informed decision. Comparative
effectiveness remains controversial, partly because few
randomized treatment trials with mortality outcomes (only one
in the PSA era) have been completed. Trials have been difficult
to complete owing to the large size and long term follow-up
needed, as well as patients’ and clinicians’ reluctance to
participate. Despite evidence indicating excellent long term
disease specific survival with observation, nearly 90% of men
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with PSA detected prostate cancer in the US receive early
treatment. In the UK, 3000-4000 RPs are carried out each year,
and two to three times this number of men undergo
radiotherapy.17 In the UK, 60% of men diagnosed with low risk
disease undergo immediate treatment; this figure is 70-90% in
the US.18
Two randomized trials compared RP to observation but were
conducted before widespread PSA testing.19 20One failed to find
a difference in overall mortality after more than 20 years.21 The
Scandinavian Prostate Cancer Group-4 trial (SPCG-4 trial)
demonstrated absolute differences in all cause and prostate
cancer related mortality at 15 years of 6.6% and 6.1%,
respectively, in favor of RP. Benefits were confined to men
under 65 years.20 Another randomized trial comparing external
beam radiotherapy with watchful waiting, also inmen diagnosed
before PSA testing, reported no significant difference in overall
or prostate cancer related mortality over at least 16 years.22
Prostate cancer mortality in these two trials was much higher
than in men with PSA detected prostate cancer.
The Prostate cancer Intervention Versus Observation Trial
(PIVOT) found that RP did not significantly reduce all cause
or prostate cancer mortality compared with observation over 15
years (fig 4⇓).23 Absolute differences were less than 3%.
Treatment effects did not differ according to age, race,
comorbidity, health status, or cancer grade. In men with PSA
values of 10 ng/mL or less or those with low risk disease,
prostate cancer mortality was rare (<3%) in men managed by
observation. Radical prostatectomy was possibly associated
with reduced all cause and prostate cancer mortality in men with
PSA greater than 10 ng/mL and high risk disease (fig 5⇓).
Complications within 30 days of surgery occurred in 21.4% of
men and included one death. Patient reported urinary
incontinence and erectile dysfunction, but not bowel
dysfunction, were more common at two years in men
randomized to surgery.
The current practice of repeated PSA testing, lower PSA
thresholds triggering biopsies, obtaining more tissue biopsy
samples, and repeating biopsies after initial negative findings
increases detection of smaller volume indolent cancers.24
Therefore, in men diagnosed currently, RP will probably result
in smaller absolute reductions in metastases and mortality and
a longer time needed to identify a reduction than were reported
in PIVOT or SPCG-4.
In contrast to observation, active surveillance involves repeat
prostate biopsies every one to two years, in addition to PSA
testing and digital rectal examination every three to four months.
If these indicate reclassification to a higher risk status, treatment
with curative intent is often started. Clinical experience with
active surveillance suggests there is an estimated risk of
metastasis of less than 1% at two to eight years.25 5ARI has
shown promising results in reducing risk reclassification on
active surveillance, but follow-up is too short to make definitive
recommendations.21Active surveillance is being compared with
surgery or radiotherapy in the UK’s ProtecT randomized trial.26
No randomized trials have assessed mortality outcomes of
external beam radiotherapy or brachytherapy versus other
management strategies in men with PSA detected prostate
cancer. Treatment of localized prostate cancer is not an approved
indication for ADT.
Radical surgery, external beam radiotherapy, or interstitial
radiotherapy can cause serious harm because they treat the whole
prostate regardless of risk, volume, or location of the cancer.
This leads to collateral damage to the external urinary sphincter,
neurovascular bundles, and rectal mucosa. Although rates of
side effects vary between treatment modalities, urinary
incontinence occurs in 10-20%, erectile dysfunction in 50%,
and rectal toxicity (diarrhea, bleeding, pain) in 10-20%.27Despite
refinements in radiotherapy (conformal, intensity modulation,
robotic radiosurgery) and radical prostatectomy (laparoscopic
or robot assisted) these harms have not changed. No large long
term RCTs have evaluated the clinical and cost effectiveness
outcomes of these newer techniques. ADT is associated with
an increased risk for impotence, hot flashes, metabolic
syndrome, gynecomastia, and other serious harms. A recent
meta-analysis of eight randomized trials in men with
non-metastatic high risk prostate cancer found that ADT was
not associated with increased mortality from cardiac disease.28
What are the future research needs?
The past few years have provided important new information
on prostate cancer prevention, detection, and treatment. Several
key research endeavors are needed to close important knowledge
gaps.
Firstly, we need to develop and evaluate novel research methods
that can be used to obtain comparative effectiveness data in a
timely and cost efficient manner but are adaptive to the
incremental technological changes that occur over the lifetime
of a study. Such studies may include designs that feature point
of care enrolment and use of cohort multiple RCT methods.29
Recent findings show that RCTs are vital for accurately
assessing the benefits and harms of prevention, detection, and
treatment strategies.
Secondly, we need better methods for population screening and
diagnostic strategies that avoid diagnosing men with clinically
insignificant prostate cancer but still identify those with
clinically important disease. Few, if any, biomarkers have been
identified that could replace or complement PSA. One strategy
that could be readily evaluated is the impact of using higher
PSA thresholds (such as 6-10 ng/mL) to define abnormality,
trigger prostate biopsy, and recommend early treatment. The
current strategy of using transrectal biopsy or histologic
outcomes from surgery as a means to validate new biomarkers
is probably flawed because of the inherent spectrum and
selection biases that result. Biomarkers require validation against
a reference standard that can be applied to all men at risk. The
target condition for detection should focus on clinically
significant cancers.30 31 Imaging research that allows the targeting
(for biopsy or treatment) of clinically significant lesions has
shown promise and requires additional study.32
Thirdly, active surveillance protocols and communication about
the benefits of observation and active surveillance need to be
improved to be acceptable to physicians and patients. The use
of a clinical examination that is inaccurate (digital rectal
examination), a blood test that lacks specificity (PSA), and a
histologic verification test (transrectal biopsy) that is temporally
unstable and can cause considerable harm may contribute to
this lack of acceptability. Results of the ongoing ProtecT study
are urgently needed to assess the trade-offs between active
surveillance versus surgery or radiotherapy, especially in men
with higher PSA concentrations or higher risk disease. Research
that uses imaging and tissue biomarkers as surveillance tools
and prognostic markers is needed.
Fourthly, comparativeness effectiveness research, especially
assessing minimally invasive treatments, using novel RCT
designs to enhance recruitment is needed before implementation.
Despite considerable overdetection and overtreatment, evidence
indicates that interventions can alter the natural course of
prostate cancer and may have clinically important benefits in
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some men. Men most likely to benefit include those with a long
life expectancy (age <65 years, excellent health status, and few
comorbidities) and those with tumors likely to cause serious
health problems (palpable prostate cancer or PSA values greater
than 10 ng/mL). Even in these men, however, the harms of
current treatments are considerable and the absolute benefit
modest. The role of minimally invasive treatments, such as
cryosurgery and high intensity focused ultrasound, has recently
been identified by the National Institute for Health and Clinical
Excellence as a priority for NHS evaluation in clinical trials or
as part of cohort registry studies.33-35 Early proof-of-concept
studies have shown that tissue preserving focal therapy—in
which the treatment is directed at the tumor rather than the whole
organ—has a low rate of side effects and may be sufficiently
effective.36
Fifthly, physicians need sufficient information, educational
resources, and communication skills to confidently and
accurately provide prevention, detection, and treatment
recommendations. Although some information exists, health
service research is needed to develop efficient and effective
tools to communicate scientific findings showing that
observation and not PSA screening is the preferred treatment
approach for most men diagnosed as having prostate cancer.
These tools will help primary care providers in their role as a
patient’s healthcare resource regarding prostate cancer.
What is the prognosis for men with
clinically localized prostate cancer?
The long term prognosis for most men with clinically localized
prostate cancer is excellent, even with no early treatment. This
is particularly true for men with prostate cancer that is detected
by PSA screening and not palpable (most men diagnosed
currently); in men with PSA values of 10 ng/mL or less; or those
with “low risk disease” defined by PSA levels (≤10 ng/mL),
tumor stage (T1 or T2a), and histologic grade (Gleason score
<6). Prostate cancer mortality over at least 15 years in these
men treated with observation is 5% or less. Nonetheless, prostate
cancer remains a leading cause of cancer related morbidity and
mortality. Men with PSA values greater than 10 ng/mL or with
high risk disease (PSA >20 ng/mL; tumor stage >T2b; Gleason
score 8-10) have a worse prognosis. Their 15 year risk of
prostate cancer mortality when managed expectantly is 20% or
more. In this group surgery seems to reduce overall and disease
mortality and bone metastases. Patients, their families,
physicians, and the public seek answers to reduce the physical,
social, and financial costs of this disease. We need better
markers of prognosis, determinants of treatment effectiveness,
and methods to effectively communicate and implement
prognostic information. We need safer and more effective
strategies and more rational use of existing options.
What should we tell patients who request
screening?
Physicians can improve the health of their male patients by
recommending against PSA screening for prostate cancer.
However, PSA screening is common, and some men will
continue to request and some physicians will continue to offer
such screening. A decision to start or continue PSA screening
should reflect an explicit understanding of the possible benefits
and harms and respect for patient preferences. The box gives
examples of screeningmessages that can be delivered in primary
care to patients who ask about PSA screening. Figure 3 provides
information about the potential benefits and harms of testing
and treatment. Community, employer based, and clinician
ordered PSA testing in the absence of well informed decision
making should be discontinued. Physicians should use higher
thresholds to define abnormalities that trigger a diagnostic
prostate biopsy in men who have undergone a PSA test, thereby
reducing overdiagnosis and overtreatment.
Compared with early intervention with surgery or radiotherapy,
observation can help most men with early stage prostate cancer
detected by PSA testing live a similar length of life and avoid
death from prostate cancer, as well as prevent treatment related
harms. Physicians should encourage patient participation in
RCTs examining new prevention, screening, and treatment
approaches.
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Prostate cancer screening messages for men
Major evidence based guidelines recommend against the prostate specific antigen (PSA) blood test for prostate cancer screening because:
• The test is unlikely to prevent you from dying of prostate cancer over 10-15 years or help you live longer
• Elevated PSA values are common and lead to additional tests that have harms
• PSA testing finds many cancers that will not cause health problems
• Once we find cancer it is hard not to treat it
• Treatments have harms that occur early, can be serious, and may persist, but have very little, if any, benefit
• By choosing not to have the PSA test you can live a similar length of life, have little to no difference in your risk of dying from prostate
cancer, and avoid the harms associated with tests, procedures, and treatments
Additional educational resources for healthcare professionals and patients
These websites provide evidence based guidelines and recommendations from the United States and United Kingdom on screening and
treatment for clinically localized prostate cancer. These resources are mainly developed by and for primary care providers and patients seen
in primary care settings. Additional society guidelines and recommendations from other countries also exist. Each listed resource contains
links to informational tools for both clinicians and patients to help in making well informed decisions about screening and treatment for
prostate cancer
Cancer Research UK. www.cancerresearch.org
UK National Screening Committee. www.screening.nhs.uk
US Preventive Services Task Force. www.uspreventiveservicestaskforce.org/prostatecancerscreening.htmAmerican
Cancer Society. www.cancer.org/healthy/informationforhealthcareprofessionals/prostatemdcliniciansinformationsource/index
Foundation for Informed Medical Decision Making.
http://informedmedicaldecisions.org/imdf_decision_aid/deciding-if-the-psa-test-is-right-for-you/
Unanswered questions
The role of new methods in conducting randomized controlled trials where recruitment has proved difficult
The role of new screening strategies such as the impact of different thresholds of prostate specific antigen (PSA) abnormality and risk
calculators on the trade-off between benefits and harms
Discovery, development, and validation of tissue and imaging (novel ultrasound, functional magnetic resonance imaging) biomarkers
to detect clinically important prostate cancer using accurate reference standards that minimize spectrum and selection bias
The role of novel tissue and imaging biomarkers in men with localized prostate cancer undergoing active surveillance
The clinical and cost effectiveness of minimally invasive whole gland and focal treatments for men with intermediate to high risk disease.
Health services research to integrate findings from PSA screening and treatment trials into primary care
A patient’s perspective
I was diagnosed with prostate cancer on my 60th birthday, with a Gleason score of 3+4, not the most welcome of birthday presents. I had
been urinating more frequently, so my general practitioner suggested doing a prostate specific antigen (PSA) test. The result was 10 ng/mL,
so my local urologist arranged a biopsy. When it came back positive, he fully explained the meaning of the results, the potential prognosis,
and treatment options. My wife accompanied me, but we could not remember much. Mention of the word “cancer” blanked out everything
else. Fortunately, the consultant jotted down the main points on several sheets of paper. We were told that there were three treatment
options—surgery, radiotherapy, and hormone treatment—watchful waiting not being considered appropriate. The main reason I chose
surgery was that if it failed it could be followed by radiotherapy, which in turn could be followed by hormone treatment. Our choice was also
colored by an emotional response. I had this “thing” growing inside me, and I wanted it got rid of and cut out quickly.
Although the postoperative PSA concentration fell to near zero, some adverse features were seen on histologic analysis. We decided not
to wait for the PSA to rise (indicating failure), but to have pre-emptive radiotherapy to the pelvic and prostate bed area three months after
surgery.
Three years later my PSA is below 0.1 ng/mL; in the short term the treatments seemed successful. The intervening period has given me
time to reflect on what has happened. I found the surgery less stressful than the radiotherapy. Although the radical prostatectomy was a
major operation, recovery seemed to follow an uphill path, with symptoms such as incontinence getting better over time. Radiotherapy
seemed much more insidious, at first seemingly benign, only later revealing the true extent of the side effects. Bowel movements took some
time to return to near normal, and incontinence was somewhat worse than it had been two months after surgery.
Although we were fully informed at every consultation about the potential side effects, we did not fully take this on board. When I was
diagnosed, we focused on the effectiveness of the treatment against the cancer. The potential side effects seemed a minor matter. Three
years later I am not so sure. Incontinence is still a problem as I use pads. I find myself acutely aware of the nearest toilet, becoming anxious
in new places. With modern technology, erectile dysfunction is manageable, but sex is not what it once was.
One unanticipated consequence is the effect of the six monthly PSA tests on me. When first told about this regimen, I was happy, thinking
that if anything developed it could be caught at an early stage. While accepting this logic, I dread the approach of each test, wondering if it
will herald the re-emergence of the cancer. However, although I get depressed, I do realize that this is something that has to be done.
Has this affected the quality of my life? To some extent it has, but I am still here, and I am grateful for that. Given the situation when diagnosed,
I am not sure that we would have done anything differently.
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Figures
Fig 1 Impact of age on the proportion of men found to have an abnormal serum prostate specific antigen concentration
depending on threshold used. The bars represent the 10 year risk of a prostate cancer related death in each age group4
Fig 2 Forest plot showing the risk ratio with 95% confidence intervals from the two (of five) randomized prostate cancer
screening trials judged to be at least “fair methodological quality” and of “low risk of bias” (PLCO and ERSPC). The vertical
line represents no benefit10
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Fig 3 Benefits and harms of screening men aged 55-69 years* with a prostate specific antigen (PSA) test every 1-4 years
for 10 years. Calculations rely on assumptions and are imprecise. Estimates should be considered in the full context of
clinical decision making and used to stimulate shared decision making10
Fig 4 Kaplan-Meier curves showing death from any cause and death from prostate cancer in the Prostate Cancer Intervention
versus Observation Trial (PIVOT) comparing radical prostatectomy with observation24
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Fig 5 Forest plots demonstrating subgroup effects (hazard ratio with 95% confidence intervals and P value for interaction)
in the Prostate Cancer Intervention versus Observation Trial (PIVOT) comparing radical prostatectomy with observation.
The vertical line indicates no effect. The size of the boxes indicates the weight of the effects24
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